Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy

Y. Miyaji, T. Tsushima, Yasutomo Nasu, M. Noda, T. Murakami, S. Kaku, S. Ebara, H. Ohmori

Research output: Contribution to journalArticle

Abstract

Interferon-α (IFN-α) was prophylactically administered to the patients with high-stage renal cell cancer after radical nephrectomy. Seventeen patients who were at high risk for recurrence of disease received 500 x 104 units of IFN-α, 2 or 3 times per week for 2 years. Median followup was 21.5 months. Of the patients 4 (23.5%) revealed pulmonary metastasis with or without local recurrence. The administration of IFN-α for 2 patients was discontinued because of side effects. One patient showing pulmonary metastasis has survived, 2 died of cancer and 1 of an unrelated cause. Immunological changes were analyzed by measurement of peripheral blood lymphocyte subsets. Two-color flow cytometry was used to evaluate the lymphocyte subsets consisting of suppressor T lymphocytes (CD8+ CD11b+), cytotoxic T lymphocytes (CD8+ CD11b-), helper T lymphocytes (CD4+ CD45 RA+), suppressor inducer T lymphocytes (CD4+ CD45 RA-), natural killer cells (CD3- CD56+), natural killer T cells (CD3+ CD56+), activated CD8 positive cells (CD8+ HLA-DR+) and activated CD4 positive cells (CD4+ HLA DR+). The number of suppressor T lymphocytes and activated CD8 positive cells increased in the recurrent cases. In contrast, suppressor T lymphocytes gradually decreased after IFN-α treatment, and no evidence of cancer was found in the remaining cases.

Original languageEnglish
Pages (from-to)1201-1207
Number of pages7
JournalBiotherapy
Volume10
Issue number9
Publication statusPublished - 1996

Fingerprint

Lymphocyte Subsets
Renal Cell Carcinoma
Interferons
HLA-DR Antigens
Helper-Inducer T-Lymphocytes
CD8-Positive T-Lymphocytes
Neoplasm Metastasis
T-Lymphocytes
Therapeutics
Recurrence
Lung
Natural Killer T-Cells
Cytotoxic T-Lymphocytes
Nephrectomy
Natural Killer Cells
Neoplasms
Flow Cytometry
Color

Keywords

  • Adjuvant therapy
  • Interferon-α
  • Lymphocyte subset
  • Renal cell cancer

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy. / Miyaji, Y.; Tsushima, T.; Nasu, Yasutomo; Noda, M.; Murakami, T.; Kaku, S.; Ebara, S.; Ohmori, H.

In: Biotherapy, Vol. 10, No. 9, 1996, p. 1201-1207.

Research output: Contribution to journalArticle

Miyaji, Y, Tsushima, T, Nasu, Y, Noda, M, Murakami, T, Kaku, S, Ebara, S & Ohmori, H 1996, 'Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy', Biotherapy, vol. 10, no. 9, pp. 1201-1207.
Miyaji, Y. ; Tsushima, T. ; Nasu, Yasutomo ; Noda, M. ; Murakami, T. ; Kaku, S. ; Ebara, S. ; Ohmori, H. / Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy. In: Biotherapy. 1996 ; Vol. 10, No. 9. pp. 1201-1207.
@article{d471c67cafce4006a4d9a132e193193a,
title = "Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy",
abstract = "Interferon-α (IFN-α) was prophylactically administered to the patients with high-stage renal cell cancer after radical nephrectomy. Seventeen patients who were at high risk for recurrence of disease received 500 x 104 units of IFN-α, 2 or 3 times per week for 2 years. Median followup was 21.5 months. Of the patients 4 (23.5{\%}) revealed pulmonary metastasis with or without local recurrence. The administration of IFN-α for 2 patients was discontinued because of side effects. One patient showing pulmonary metastasis has survived, 2 died of cancer and 1 of an unrelated cause. Immunological changes were analyzed by measurement of peripheral blood lymphocyte subsets. Two-color flow cytometry was used to evaluate the lymphocyte subsets consisting of suppressor T lymphocytes (CD8+ CD11b+), cytotoxic T lymphocytes (CD8+ CD11b-), helper T lymphocytes (CD4+ CD45 RA+), suppressor inducer T lymphocytes (CD4+ CD45 RA-), natural killer cells (CD3- CD56+), natural killer T cells (CD3+ CD56+), activated CD8 positive cells (CD8+ HLA-DR+) and activated CD4 positive cells (CD4+ HLA DR+). The number of suppressor T lymphocytes and activated CD8 positive cells increased in the recurrent cases. In contrast, suppressor T lymphocytes gradually decreased after IFN-α treatment, and no evidence of cancer was found in the remaining cases.",
keywords = "Adjuvant therapy, Interferon-α, Lymphocyte subset, Renal cell cancer",
author = "Y. Miyaji and T. Tsushima and Yasutomo Nasu and M. Noda and T. Murakami and S. Kaku and S. Ebara and H. Ohmori",
year = "1996",
language = "English",
volume = "10",
pages = "1201--1207",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "9",

}

TY - JOUR

T1 - Measurement of peripheral blood lymphocyte subsets in patients with renal cell cancer treated with postoperative adjuvant interferon-α therapy

AU - Miyaji, Y.

AU - Tsushima, T.

AU - Nasu, Yasutomo

AU - Noda, M.

AU - Murakami, T.

AU - Kaku, S.

AU - Ebara, S.

AU - Ohmori, H.

PY - 1996

Y1 - 1996

N2 - Interferon-α (IFN-α) was prophylactically administered to the patients with high-stage renal cell cancer after radical nephrectomy. Seventeen patients who were at high risk for recurrence of disease received 500 x 104 units of IFN-α, 2 or 3 times per week for 2 years. Median followup was 21.5 months. Of the patients 4 (23.5%) revealed pulmonary metastasis with or without local recurrence. The administration of IFN-α for 2 patients was discontinued because of side effects. One patient showing pulmonary metastasis has survived, 2 died of cancer and 1 of an unrelated cause. Immunological changes were analyzed by measurement of peripheral blood lymphocyte subsets. Two-color flow cytometry was used to evaluate the lymphocyte subsets consisting of suppressor T lymphocytes (CD8+ CD11b+), cytotoxic T lymphocytes (CD8+ CD11b-), helper T lymphocytes (CD4+ CD45 RA+), suppressor inducer T lymphocytes (CD4+ CD45 RA-), natural killer cells (CD3- CD56+), natural killer T cells (CD3+ CD56+), activated CD8 positive cells (CD8+ HLA-DR+) and activated CD4 positive cells (CD4+ HLA DR+). The number of suppressor T lymphocytes and activated CD8 positive cells increased in the recurrent cases. In contrast, suppressor T lymphocytes gradually decreased after IFN-α treatment, and no evidence of cancer was found in the remaining cases.

AB - Interferon-α (IFN-α) was prophylactically administered to the patients with high-stage renal cell cancer after radical nephrectomy. Seventeen patients who were at high risk for recurrence of disease received 500 x 104 units of IFN-α, 2 or 3 times per week for 2 years. Median followup was 21.5 months. Of the patients 4 (23.5%) revealed pulmonary metastasis with or without local recurrence. The administration of IFN-α for 2 patients was discontinued because of side effects. One patient showing pulmonary metastasis has survived, 2 died of cancer and 1 of an unrelated cause. Immunological changes were analyzed by measurement of peripheral blood lymphocyte subsets. Two-color flow cytometry was used to evaluate the lymphocyte subsets consisting of suppressor T lymphocytes (CD8+ CD11b+), cytotoxic T lymphocytes (CD8+ CD11b-), helper T lymphocytes (CD4+ CD45 RA+), suppressor inducer T lymphocytes (CD4+ CD45 RA-), natural killer cells (CD3- CD56+), natural killer T cells (CD3+ CD56+), activated CD8 positive cells (CD8+ HLA-DR+) and activated CD4 positive cells (CD4+ HLA DR+). The number of suppressor T lymphocytes and activated CD8 positive cells increased in the recurrent cases. In contrast, suppressor T lymphocytes gradually decreased after IFN-α treatment, and no evidence of cancer was found in the remaining cases.

KW - Adjuvant therapy

KW - Interferon-α

KW - Lymphocyte subset

KW - Renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=0029839859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029839859&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029839859

VL - 10

SP - 1201

EP - 1207

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 9

ER -